TABLE 3
FROM:
Immunopolarization of CD4+ and CD8+ T Cells to Type-1–Like is Associated with Melanocyte Loss in Human Vitiligo
Anna Wa
kowicz-Kaliska, René M J G J van den Wijngaard, Bert J Tigges, Wiete Westerhof, Graham S Ogg, Vincenzo Cerundolo, Walter J Storkus and Pranab K Das
Table 3. Mean Production (
SD) of Different Cytokines by TCC Isolated from NL and PL Skin of Four Active Vitiligo Patients and One Stable Vitiligo Patient
| Production of cytokines by NL TCC ng/ml | Production of cytokines by PL TCC ng/ml | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T cell subsetsa | Active vitiligo TCC (n = 92) | Stable vitiligo TCC (n = 38) | Active vitiligo TCC (n = 157) | Stable vitiligo TCC (n = 38) | ||||||||||||||||
| IL-5 | IL-6 | IL-10 | IL-13 | TNF- | IL-5 | IL-6 | IL-10 | IL-13 | TNF- | IL-5 | IL-6 | IL-10 | IL-13 | TNF- | IL-5 | IL-6 | IL-10 | IL-13 | TNF- | |
| Type 0 | 1.4 2.0 | 0.3 0.4 | 0.1 0.2 n = 50 | 12 13 | 10 11 | 4.1 10.1 | 0.06 0.1 | 0.02 0.02 n = 19 | 12 8.0 | 6.2 5.2 | 0.75 2.7 | 0.06 0.12 | 0.06 0.09 n = 51 | 3.6 5.3 | 20 38 | 2.6 3.3 | 0.07 0.06 | 0.05 0.12 n = 27 | 11.6 9 | 12.8 19.1 |
| Type 1 | 0.4 0.6 | 0.07 0.1 | 0.07 0.03 n = 33 | 4.2 4.2 | 9.8 9.1 | 0.09 0b
| 0.01 0b
| 0.02 0b n = 1 | 2.0 0b
| 8.7 0b
| 0.27 0.33 | 0.13 0.26 | 0.08 0.09 n = 106 | 3.2 2.9 | 24 53 | 0.15 0.08 | 0.08 0.01 | 0.04 0.03 n = 2 | 1.9 0.01 | 0.42 0.01 |
| Type 2 | 15.3 32.5 | 0.41 0.32 | 0.04 0.04 n = 9 | 15 13 | 30 17 | 1.5 0.7 | 0.03 0.03 | 0.01 0.01 n = 18 | 8.3 7.9 | 2.6 1.8 | 0c | 0c | 0c n = 0 | 0c | 1.07 1.18 | 0.15 0.18 | 0.01 0.01 | 10.2 10.6 n = 9 | 3.69 6.19 | |
a The classification of the clones was determined based on their IFN
/IL-4 ratio as previously reported (Verhagen et al, 1998). Clones with the ratio 
20 were considered to be Type-1. Clones with the ratio 
0.4 were considered to be Type-2. The remaining clones were qualified as Type-0.
b One Type 1 clone was isolated from stable vitiligo patient.
c No Type 2 TCC were isolated from active vitiligo patients.
NL, nonlesional; PL, perilesional; TCC, T-cell clones.
